Pharmaceutical company conducts a clinical trial of Eptinezumab in Adults With Migraine and Medication Overuse Headache
The company H. Lundbeck A/S is enrolling patients into the clinical trial investigating Eptinezumab in Adults With Migraine and Medication Overuse Headache (Sunlight).
This study evaluates the efficacy of eptinezumab to prevent migraine and headache in patients with the combined diagnosis of migraine and medication overuse headache
The trial is designed to enroll male and female 18 Years to 75 Years and is being conducted in the ES4007 Hospital Universitario La Paz - PPDS, Madrid, Spain.
The study start date is February 17, 2021.
The patients that can be enrolled into this study include:
- The patient has a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 guidelines confirmed at the Screening Visit with a history of migraine onset of at least 12 months prior to the Screening Visit.
- The patient has ≥8 migraine days per month for each month on average within the past 3 months prior to the Screening Visit.
- The patient has a diagnosis of medication overuse headache (MOH) as defined by IHS ICHD-3 guidelines.
- The patient has headache on ≥15 days/month for each month within the past 3 months prior to the Screening Visit.
and others.
The population that are excluded from participation:
- The patient has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway.
- The patient has confounding and clinically significant pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome).
- The patient has a diagnosis of acute or active temporomandibular disorder.
- The patient has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), recurrent painful ophthalmoplegic neuropathy, migraine with brainstem aura and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
The full list can be viewed at the link below.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT04772742
